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ABSTRACT
INVESTIGATING EFFECTS OF THE ANTIBIOTIC
CIPROFLOXACIN ON THE DOPAMINERGIC SH-SY5Y CELL
LINE
SEPTEMBER 2015
JEFFREYS NATHANIEL JOHNSON
B.A., CORNELL UNIVERSITY
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor James J. Chambers
Ciprofloxacin is a widely prescribed antibiotic which causes idiopathic sensory adverse
effects and is known to induce oxidative stress. Dopaminergic cells are known to have
intrinsic sensitivity to oxidative stress. To investigate whether ciprofloxacin potentiates cy-
totoxicity of dopamine, effects of combined drug treatments on cell viability were assessed by
resazurin reduction, and effects on mitochondrial health were assessed by morphology. The
cell viability assays suggest that ciprofloxacin significantly potentiates dopamine cytotoxicity
at clinically relevant doses, although dopamine possibly interferes with the viability assay.
Effects of drug treatments on mitochondrial morphology were inconclusive.
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CHAPTER 1
INTRODUCTION
1.1 Ciprofloxacin
NN
F
O
OH
O
HN
Figure 1.1: Structure of ciprofloxacin.
Ciprofloxacin is a fluoroquinolone broad-spectrum bacteriocidal antibiotic used to treat
a wide variety of infections. It works by inhibiting bacterial DNA gyrase and topoisomerase
IV, which are required for DNA synthesis.
Historically, incidence of adverse effects had been estimated at about 13% of treated pa-
tients, with incidence of mild CNS-related adverse effects (headache and dizziness, resolving
within days) estimated at about 1% [10]. This has led to its prophylactic use, for example
in postal workers who are at risk of coming into contact with bioterror agents [13].
More recently, ciprofloxacin has been associated with acute psychiatric adverse reactions
(mania, psychosis, seizures) and with peripheral neuropathy [106]. Of the cases involving
neurological adverse effects, 42% reported disturbances in function of olfactory, visual, or
auditory senses [24,106]. In 2013, the FDA amended the label of ciprofloxacin to reflect the
“serious side effect of peripheral neuropathy, [which] may occur soon after these drugs are
taken and may be permanent [3].”
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While some neuropsychiatric and drug interaction-related adverse effects are attributed
to inhibition of Cytochrome P450 and inverse agonism of ionotropic γ-aminobutyric acid
receptors, the etiology of ciprofloxacin-induced neuropathy and sensory dysfunction is un-
known [106].
1.2 Mitochondria and oxidative stress
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Figure 1.2: A few reactions available to dopamine and its oxidation products. Autooxidation
of catechols into quinones by O2 typically proceeds via a radical semiquinone intermediate.
Quinones may participate in Michael additions with nucleophilic protein sidechains or DNA
bases to form covalent adducts. Adapted from [46, 69, 86, 105].
Emerging evidence suggests that fluoroquinolone antibiotics, including ciprofloxacin, dis-
rupt mitochondrial function and induce oxidative toxicity in mammalian cells. Mitochondria
are organelles responsible for a wide variety of metabolic functions, including energy con-
version via oxidative phosphorylation. In this process, high-energy electrons belonging to a
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1⁄2 reaction E ?o Function Reference
Resazurin + 2 e– + 2H+ Resorufin +380mV Viability indicator [1]
2CytC Fe +3 + 2 e– 2CytC Fe +2 +254mV ETC electron carrier [73]
Ubiquinone + 2 e– + 2H+ Ubiquinol +45mV ETC electron carrier [52]
(BOUND) FAD + 2 e– + 2H+ FADH2 +3-+91mV ETC electron carrier [73]
(BOUND) FMN + 2 e– + 2H+ FMNH2 +3-+91mV ETC electron carrier [73]
Dopaminequinone + 2 e– + 2H+ Dopamine -151mV - -300mV Dopamine oxidation product [32, 105, 112]
DOPAL Quinone + 2 e– + 2H+ DOPAL -161mVmV Dopamine oxidation product [68]
Dopaminochrome + 2 e– + 2H+ Leukoaminochrome -259mV Dopamine oxidation product [32]
NAD+ + 2 e– + 2H+ NADH + H+ -320mV Electron donor to ETC [52]
NADP+ + 2 e– + 2H+ NADPH + H+ -324mV Electron donor to ETC [52]
GlutathioneS SGlutathione + + 2 e– + 2H+ 2GlutathioneSH -230–340mV Intracellular antioxidant [73]
CysS SCys + 2 e– + 2H+ 2CysSH -340mV Nucleophilic protein sidechain [52]
Table 1.1: Reduction potentials. All half-reaction reduction potentials E ?o and reaction
potentials Eh are empirically determined in dilute solutions, pH 7-7.5, relative to stan-
dard hydrogen electrode. A reduction/oxidation reaction between two species is ther-
modynamically favored if the sum of half-reaction potentials E ?o is positive. So, for ex-
ample, dopamine can reduce ubiquinone (Dopamine + Ubiquinone + 2 e– + 2 H+
Dopaminequinone + Ubiquinol + 2 e– + 2H+,Eh = E ?o,ubiquinone+−1∗E ?o,dopamine = +206mV )
but dopamine cannot reduce NAD+ (Eh = E ?o,NAD+ +−1 ∗ E ?o,dopamine = −159mV )
reduced substrate such as NADH are transferred through a series of proteins referred to as
the electron transport chain (ETC), where a small amount of energy is used at each step in
the chain to pump protons against a concentration gradient. The ETC proteins, Complexes
I-IV, are large (162-850kDa) multisubunit (4-30) proteins; all of Complex I and IV and part
of Complex III are encoded by the mitochondrial genome [74].
Reactions which transfer electrons are referred to as redox reactions (reduction, accepting
electrons; oxidation, donating electrons). Electron transfer within and between ETC com-
plexes occurs via reversible redox reactions of prosthetic groups covalently bound to proteins.
These prosthetic groups are typically quinones (FMN, FAD, Ubiquinone) or transition metals
(Fe(II/III), Cu(I/II)) [74].
Electron transfer between these prosthetic groups is typically favorable due to their spa-
tial arrangement. Reduction by an external agent renders electron acceptors incapable of
accepting electrons, while disruption of ETC protein structure alters the spatial arrangement
of electron carriers such that electron transfer between them becomes less favorable. When
3
there is no acceptor (oxidized carrier) available to accept electrons from a donor (reduced
carrier), these electrons are then available to participate in other reactions, a process termed
‘leakage’ [74, 108].
Typically, this leakage occurs as reduction of oxygen to reactive oxygen species (ROS)
such as superoxide (O−•2 ). These compounds irreversibly modify a wide variety of proteins,
lipids, and DNA, a process thought to mediate cellular damage [9,96]. While mitochondrial
ROS have been established as essential intracellular signaling molecules and are regulated in
production and degradation, excessive ROS production is pathological [96].
The exact kinetics and locations of electron leakage from reduced carriers remains an
active area of investigation. Emerging evidence suggests that the majority of pathologi-
cal superoxide generation is associated with reduction of the electron carriers FMN and
ubiquinone at Complex I, although the other complexes are also susceptible to inhibition
and produce superoxide [61, 79, 108, 117].
Dopamine contributes to oxidative stress by multiple mechanisms. Autooxidation of
dopamine and dopamine-derived catechols (For an overview of dopamine-derived reactive
species, see Figure 1.2) into quinones by ambient oxygen proceeds by a two step radical
mechanism which produces 2 molecules of superoxide per one molecule of dopamine converted
to quinone. Dopamine quinone can then be reduced back to dopamine by biological reducing
agents and again undergo autooxidation, a process termed redox cycling. Or, the quinone
can participate in a Michael addition with biological nucleophiles to form covalent adducts
with protein sidechains and DNA bases. This can cause superoxide to be generated at
ETC proteins by the mechanisms discussed above. Dopamine, and some of its oxidation
products, are also capable of reducing mitochondrial ETC electron carriers (For some possible
interactions between ETC electron carriers and dopamine, see Table 1.1) leading to electron
leakage and superoxide production.
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Turnover of mitochondrial ETC proteins is on the order of days [54,84]. Longer turnover
time correlates with decreased enzymatic activity and increased ROS production, and dis-
rupting mitochondrial protein turnover causes decreased activity and increased ROS pro-
duction [80, 104]. Manipulations which damage mtDNA are known to increase production
of ROS [43].
Interestingly, under the endosymbiotic theory of mitochondrial evolution [64], it is plau-
sible that mitochondrial DNA (mtDNA) maintenance genes may be sufficiently similar to
bacterial DNA maintenance genes as to be sensitive to drugs which inhibit bacterial DNA
replication. Disrupted mitochondrial topoisomerase function is known to decrease respira-
tory capacity and increase ROS production [100].
Kalghatgi et. al. [48] found that clinically relevant doses of ciprofloxacin and similar
antibiotics inhibit mitochondrial ETC complexes I and IV, cause accumulation of various
reactive oxygen species, and elevate numerous biomarkers of oxidative damage and mito-
chondrial dysfunction.
Ciprofloxacin is cytotoxic to mammalian cells in a manner dependent on mitochondrial
respiration, and causes mtDNA double-stranded breaks with maximal effect at 30µg/ml.
While ROS directly damage mtDNA and damaged mtDNA causes increased ROS production,
mtDNA isolated from ciprofloxacin-treated cells show site-specific breaks with 5’-attached
proteins, consistent with disruption of topoisomerase II-like activity rather than the non-
specific breaks and degraded bases expected of mtDNA damaged by ROS [65]. Similar
quinolone antibiotics have also been shown to disrupt DNA maintenance in isolated rat mi-
tochondria [21], and fluoroquinolones have been shown to disrupt mitochondrial energetics
and cell viability in a ROS-dependent manner [11, 39]
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1.3 Dopaminergic cells
Dopamine is a catecholaminergic neurotransmitter. In the central nervous system, it
is synthesized in several discrete nuclei which regulate executive function, motor gating,
and homeostasis. Dopamine is also synthesized in retinal interneurons and olfactory bulb
interneurons. In the peripheral nervous system, dopamine is synthesized in sympathetic
ganglia and gut neurons. Dopamine is also synthesized transiently in central noradrenergic
neurons and peripheral adrenal medulla cells [49].
Dopaminergic cells are particularly sensitive to mitochondrial stress. The lesioning
agents MPP+ and 6-OH-dopamine disrupt mitochondrial electron transport, causing ox-
idative stress and cell death. These compounds specifically accumulate in dopaminergic cells
because they are substrates of the dopamine transporter (DAT) [26, 75, 93].
Rotenone is a non cell type specific complex I inhibitor that induces ROS production in all
cell types. However, chronic sublethal rotenone treatment specifically lesions dopaminergic
cells [16]. This susceptibility of dopaminergic cells to rotenone is thought to involve elevated
intracellular dopamine mediated by VMAT2 inhibition [16, 23], or cooperative complex I
inhibition by rotenone and dopamine metabolites [116].
Various manipulations which directly increase intracellular dopamine, including appli-
cation of extracellular dopamine to DAT-expressing cells, also lead to oxidative stress and
death [6, 14, 19, 45].
Dopamine undergoes a series of reactions, partially depicted in Figure ??. Intracellular
dopamine is thought to contribute to oxidative stress by multiple mechanisms. Dopamine
and many of its oxidation products are redox-active, and have reduction potentials suffi-
ciently low so that they can reduce electron carriers directly and inhibit electron transport
complexes (see Table 1.1) [4, 22, 116]. Also, several stable dopamine oxidation products are
reactive quinones which irreversibly modify mitochondrial ETC proteins [15, 103], typically
via Michael additions to thiols or other nucleophiles [38, 41].
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Taken together, it is plausible that dopaminergic cells are uniquely susceptible to ciprofloxacin-
induced stress, as ciprofloxacin-mediated impairment of ETC protein turnover could exacer-
bate dopamine-mediated damage to ETC proteins, leading to increased oxidative stress and
cell death. Also, ciprofloxacin-upregulated superoxide may promote single electron oxidation
of dopamine and redox cycling which further promotes mitochondrial ROS generation. This
could underly the idiopathic sensory adverse effects reported by some ciprofloxacin treated
patients.
Olfaction is known to be sensitive to dopaminergic stress. Rats with lesioned TH+
olfactory bulb cells exhibit both anosmia and parosmia. These animals display reduced
behavioral responses to some attractive and aversive olfactory cues, and display aversive
behavior when presented with the typically attractive scent of female urine [66].
This disruption of olfactory function induced by dopaminergic olfactory bulb cell lesion in
rats is consistent with the disruption of olfactory function reported by ciprofloxacin-treated
humans.
1.4 Current study: Motivations and hypothesis
In this work, I will investigate whether ciprofloxacin renders dopaminergic cells more
sensitive to dopamine toxicity, using SH-SY5Y cells as a model for olfactory bulb TH+
neurons. If ciprofloxacin exacerbates stress on dopaminergic cells, this will exemplify a new
class of drug interactions with quinolone antibiotics.
DAT inhibitors which increase extracellular dopamine are widely prescribed as psychi-
atric medications, and are also popular drugs of abuse. Dopaminergic stimulants such as
amphetamines [20, 25] and dopamine prodrugs such as L-DOPA [6], in typical doses, are
known to cause mitochondrial dysfunction and oxidative toxicity in a manner consistent
with elevated intracellular dopamine mediated by vesicular monoamine transporter (VMAT)
inhibition. If this toxicity is potentiated by quinolone antibiotics, then co-administration of
7
quinolones with dopaminergic drugs should be avoided and the interaction should be char-
acterized in vivo.
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CHAPTER 2
METHODS
In the first set of experiments, a cell viability assay was used to determine whether
ciprofloxacin exacerbates toxicity of exogenous dopamine in SH-SY5Y cells.
Differentiated SH-SY5Y cells were treated with varying concentrations of dopamine and
ciprofloxacin, separately, to establish dose-response relationships between drug and loss of
cell viability. Cells were also be treated with combinations of both drugs to establish syn-
ergistic toxicity. Cell viability was then assessed by resazurin reduction and measured by
fluorescence.
2.1 Common methods
2.1.1 Cell culture
SH-SY5Y cells are a dopaminergic neuron-like adherent cell line. When differentiated
with retinoic acid (RA), they develop a polarized morphology and express tyrosine hydroxy-
lase (TH) and DAT [34,60]. SH-SY5Y cells are widely used in models of dopaminergic neuron
toxicity, and are sensitive to exogenous dopamine [19,45] and other dopamine neuron-specific
stressors [60].
Unless otherwise noted, all consumables were purchased from Fisher Scientific. SH-SY5Y
cells (kindly provided by Johan Sunryd and Rafael Fissore, University of Massachusetts
Amherst), were maintained in DMEM (CellGro, Corning) with 4.5g/l glucose, 2mM l-
glutamine, 5% serum (FetalClone II, GE Healthcare), in a humidified incubator (HeraCell
150, Thermo Scientific) at 37C. Media pH was maintained at 7.3-7.4 with bicarbonate in
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a 5% CO2 atmosphere. At approximately 75% confluence, cells were trypsinized in DPBS,
centrifuged, and subcultured into dishes or well plates. After 8 passages, cells were discarded
and new lines were grown from stocks stored at -80C.
To differentiate cells, maintenance media was replaced with differentiation media; low
serum DMEM (1% serum) with 10µM retinoic acid (Tocris), added from 1000x stocks in
DMSO [45, 50, 60].
For viability assays, cells in differentiation media were seeded into plasma-treated 96-
well plates at a density of approximately 10000-15000 cells/well in a volume of 50µl. Unless
otherwise noted, experiments were performed after 3 days of differentiation.
For imaging assays, acid-washed 12mm glass coverslips were placed in 4-well dishes and
pretreated overnight with 0.5mg/ml poly-l-lysine in sterile filtered sodium tetraborate buffer,
pH 8.3. Treated coverslips were washed 5 times in sterile DI water, thoroughly dried, and
seeded with cells in differentiation media at a density of approximately 40000-60000 cells per
well in a volume of 500µl. Experiments were performed after 3 days of differentiation.
2.1.2 Treatment conditions
Due to availability, exogenous dopamine•HCl was used to induce dopaminergic stress,
instead of the more clinically relevant L-DOPA or amphetamine.
Drug solutions were freshly prepared from solid immediately prior to treatments. First,
concentrated stocks were prepared. Dopamine•HCl (Acros Organics) was dissolved in DI
water at 33.2mg/ml and sterile filtered. Ciprofloxacin (Acros Organics) was dissolved at
20mg/ml in 0.1N HCl and sterile filtered.
Concentrated stocks were then diluted to 7x concentration of the most concentrated
dosage in serum-free DMEM (with phenol red pH indicator), and lower dosages were prepared
as serial dilutions in serum-free DMEM. Media pH was monitored by phenol red color. These
10
dilutions were then applied to cells in well plates, which were incubated for 18-24 hours and
then subjected to assays as described below.
For 96-well plate fluorescence assays, two columns (8 wells each) were used as positive and
negative controls for normalizing fluorescence. Serum-free DMEM was used as the positive
control, while 0.1% Triton X-100, a nonionic detergent, was used as the negative control.
2.1.3 Viability assay
Cell viability was be assessed using resazurin (commonly known as Alamar Blue), a
fluorogenic cell viability indicator. Non-fluorescent resazurin is reduced into fluorescent
resorufin at several locations within the mitochondrial electron transport chain. It acts as
a direct indicator of mitochondrial respiratory function and as an indirect indicator of cell
viability; loss of mitochondrial respiratory ability leads to less fluorescence [82].
To perform viability assays, resazurin (Acros Organics) was dissolved in DI water at
10mg/ml and added to wells at a final concentration of 10µg/ml. After a four hour incu-
bation at 37C, 5µl of isopropyl alcohol was added to wells to remove bubbles, and plates
were immediately imaged on a plate reader (SpectraMax M5, Molecular Devices). 590nm
fluorescence with 560nm excitation, all other parameters automatically determined, was read
from the top of the plate.
Using Prism 6.0 (Graphpad Software), fluorescence values were normalized, with the
mean of positive (media only) wells defined as 100% and the mean of negative (Triton X-
100) wells defined as 0%. A 5-parameter sigmoidal function Y = bottom+ top−bottom1+10(log(IC50)−X)∗slope
was fitted to the data, with log([Dopamine]) as the independent variable and normalized
fluorescence as the dependent value. The parameter IC50 (inhibitory concentration 50%)
is a treatment concentration which causes a 50% decrease in the dependent variable of an
assay. IC50 values were compared with an F-test performed as part of the nonlinear fitting
procedure.
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2.2 Effect of differentiation on SH-SY5Y sensitivity to dopamine
If SH-SY5Y cells are sensitive to dopamine in a manner which depends on expres-
sion of dopamine transporter, differentiated cells are expected to have a lower IC50 value
than undifferentiated cells for cell viability inhibition by dopamine. Therefore, dopamine
IC50(viability) values should provide an indicator of differentiation status. This experiment
also established IC50 values for dopamine for purposes of planning further experiments.
Cells were seeded in 96-well plates. Cells to be differentiated were plated in differen-
tiation media with retinoic acid, while cells to serve as the undifferentiated control were
plated in DMEM+1%serum. After a 5 day incubation, cells were treated with dopamine in
concentrations ranging from 1.0mM to 50.8nM by 3-fold serial dilution, with 16 wells among
2 plates per each dosage of dopamine. After overnight incubation, media was replaced with
serum free DMEM and cells were subjected to the resazurin reduction viability assay.
2.3 Effect of ciprofloxacin on SH-SY5Y viability
The purpose of this work is to investigate whether ciprofloxacin treatment at concentra-
tions subthreshold for viability loss enhance dopamine toxicity. The dose dependence of cell
viability on ciprofloxacin was therefore investigated.
Cells were seeded in 96 well plates with differentiation media. After 3 days of incubation,
cells were treated with ciprofloxacin in concentrations ranging from 1250µg/ml to 0.64ng/ml
by 5-fold serial dilution, with 16 wells among 2 plates per each dosage of ciprofloxacin. The
highest ciprofloxacin concentration were limited by solubility. After overnight incubation,
cells were then subjected to the resazurin reduction viability assay. Curve fitting was not
performed, as the highest soluble concentration of ciprofloxacin was not sufficient to kill a
majority of cells.
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2.4 Cell-free controls
To establish whether or not dopamine or ciprofloxacin reduce resazurin on their own,
cell-free controls of the resazurin viability assay were performed.
To 70 µl of differentiation media was added ciprofloxacin in concentrations ranging from
1250µg/ml to 0.64ng/ml by 5-fold serial dilution, with 8 wells per concentration per plate
and 2 plates total. To 70 µl of differentiation media was added dopamine in concentrations
ranging from 6.25mM to 3.2nM by 5-fold serial dilution, with 8 wells per concentration per
plate and 2 plates total. After overnight incubation at 37C, to one plate each of ciprofloxacin
and dopamine was added 10µl resazurin to final concentration of 10µM, and to the remaining
two plates was added 10µl of serum-free DMEM. After a 4 hour incubation, fluorescence
was read as in the viability assay. Fluorescence spectra (460nm excitation) and absorbsion
spectra were also acquired on the same plate reader.
2.5 Combined ciprofloxacin and dopamine treatment (2 ciprofloxacin
doses)
To determine whether ciprofloxacin enhances dopamine toxicity, dose-response curves
of cell viability inhibition by dopamine were compared between ciprofloxacin-treated cells
and untreated cells. 10µg/ml was chosen as a physiologically relevant [2] and subthreshold
(see 3.2) dosage. 40µg/ml was chosen as a suprathreshold dosage, because double-stranded
mtDNA breaks have been observed in cultured cells at 30µg/ml [65].
Cells were seeded in 96-well plates with differentiation media. After a 3 day incubation,
cells were treated with dopamine in concentrations ranging from 250µM to 400nM by 5-fold
serial dilution, with 16 wells per plates per dosage of dopamine. 8 wells of each dopamine
dosage per plate were treated with 10µg/ml or 40µg/ml ciprofloxacin, with 2 plates per
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ciprofloxacin dosage. After overnight incubation, cells were then subjected to the resazurin
reduction viability assay.
Dopamine/µM
250 50 10 2 0.4 250 50 10 2 0.4 100% 0%
(250, 0) (50, 0) (10, 0) (2, 0) (0.4, 0) (250, 10) (50, 10) (10, 10) (2, 10) (0.4, 10) Media TX100
(250, 0) (50, 0) (10, 0) (2, 0) (0.4, 0) (250, 10) (50, 10) (10, 10) (2, 10) (0.4, 10) Media TX100
(250, 0) (50, 0) (10, 0) (2, 0) (0.4, 0) (250, 10) (50, 10) (10, 10) (2, 10) (0.4, 10) Media TX100
(250, 0) (50, 0) (10, 0) (2, 0) (0.4, 0) (250, 10) (50, 10) (10, 10) (2, 10) (0.4, 10) Media TX100
(250, 0) (50, 0) (10, 0) (2, 0) (0.4, 0) (250, 10) (50, 10) (10, 10) (2, 10) (0.4, 10) Media TX100
(250, 0) (50, 0) (10, 0) (2, 0) (0.4, 0) (250, 10) (50, 10) (10, 10) (2, 10) (0.4, 10) Media TX100
(250, 0) (50, 0) (10, 0) (2, 0) (0.4, 0) (250, 10) (50, 10) (10, 10) (2, 10) (0.4, 10) Media TX100
(250, 0) (50, 0) (10, 0) (2, 0) (0.4, 0) (250, 10) (50, 10) (10, 10) (2, 10) (0.4, 10) Media TX100
No Cipro 10 µg/ml Cipro
Table 2.1: Treatment conditions per plate, as ([Dopamine],[Cipro])
2.6 Combined ciprofloxacin and dopamine treatment (8 ciprofloxacin
doses)
To further characterize the enhancement of dopamine toxicity by ciprofloxacin, a wider
range of dopamine and ciprofloxacin dosages were compared. As in the previous experi-
ment, dose-response curves of cell viability inhibition by dopamine were compared between
ciprofloxacin-treated cells and untreated cells.
Cells were seeded in 96-well plates with differentiation media. After a 3 day incubation,
cells were treated with dopamine in concentrations ranging from 1.25mM to 16nM by 5-fold
serial dilution and with ciprofloxacin in concentrations ranging from 1250µg/ml to 0.64ng/ml
by 5-fold serial dilution. Each dosage combination of ciprofloxacin and dopamine occupied 1
well per plate, with 8 plates treated in total. After overnight incubation, cells were subjected
to the viability assay.
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Dopamine/µM
1250 250 50 10 2 0.4 0.08 0.016 0.0032 0.00064 100% 0%
1250 (1250, 1250) (1250, 250) (1250, 50) (1250, 10) (1250, 2) (1250, 0.4) (1250, 0.08) (1250, 0.016) (1250, 0.0032) (1250, 0.00064) Media TX100
250 (250, 1250) (250, 250) (250, 50) (250, 10) (250, 2) (250, 0.4) (250, 0.08) (250, 0.016) (250, 0.0032) (250, 0.00064) Media TX100
50 (50, 1250) (50, 250) (50, 50) (50, 10) (50, 2) (50, 0.4) (50, 0.08) (50, 0.016) (50, 0.0032) (50, 0.00064) Media TX100
Cipro/ µgml 10 (10, 1250) (10, 250) (10, 50) (10, 10) (10, 2) (10, 0.4) (10, 0.08) (10, 0.016) (10, 0.0032) (10, 0.00064) Media TX100
2 (2, 1250) (2, 250) (2, 50) (2, 10) (2, 2) (2, 0.4) (2, 0.08) (2, 0.016) (2, 0.0032) (2, 0.00064) Media TX100
0.4 (0.4, 1250) (0.4, 250) (0.4, 50) (0.4, 10) (0.4, 2) (0.4, 0.4) (0.4, 0.08) (0.4, 0.016) (0.4, 0.0032) (0.4, 0.00064) Media TX100
0.08 (0.08, 1250) (0.08, 250) (0.08, 50) (0.08, 10) (0.08, 2) (0.08, 0.4) (0.08, 0.08) (0.08, 0.016) (0.08, 0.0032) (0.08, 0.00064) Media TX100
0.016 (0.016, 1250) (0.016, 250) (0.016, 50) (0.016, 10) (0.016, 2) (0.016, 0.4) (0.016, 0.08) (0.016, 0.016) (0.016, 0.0032) (0.016, 0.00064) Media TX100
Table 2.2: Treatment conditions per plate, as ([Cipro],[Dopamine])
2.7 Effects of ciprofloxacin and dopamine on mitochondrial mor-
phology
Fluorescent mitochondria, which appear as an extended reticulated network in healthy
cells, were identified using image processing techniques. The morphological parameters such
as aspect ratio and inverse circularity were compared among treatment groups to assess mi-
tochondrial fragmentation. Altered mitochondrial morphology, especially fragmentation, is
a hallmark of mitochondrial stress and dysfunction [47,114,115], and both ciprofloxacin [48]
and dopamine [56] are reported to alter mitochondrial morphology in a manner consis-
tent with fragmentation. In the second set of experiments, the effects of dopamine and
ciprofloxacin on mitochondrial morphology in SH-SY5Y cells were characterized to deter-
mine whether ciprofloxacin treatment leads to increased mitochondrial fragmentation in
dopamine-treated cells.
SH-SY5Y cells were be plated on poly-D-lysine treated glass coverslips in differentiation
media. After a 3 day incubation, cells were treated overnight with combinations of dopamine
(0µM, 2µM, 10µM, 50µM) and ciprofloxacin (0µg/ml, 100µg/ml, 500µg/ml).
For imaging, drug-containing differentiation media was replaced with fresh serum-free
DMEM containing 150nM MitoTracker Green (Life Technologies) and cells were incubated
for 30 minutes at 37C [115]. Coverslips were labeled with MitoTracker individually prior to
imaging. After incubation, coverslips were washed twice with extracellular solution (138mM
NaCl, 1.5mM KCl, 1.2mM MgCl2, 2.5mM CaCl2, 5mM HEPES, 14mM glucose, pH adjusted
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to 7.4 with NaOH) and mounted in a perfusion chamber containing extracellular solution at
room temperature.
Labeled cells were then imaged on an epifluorescence microscope (Nikon Eclipse TI) with
a 40x NA 0.75 air objective (CFI Plan Fluor DLL), 4x neutral density filter and GFP filter
set and photographed (150ms exposure, gain 5, 161nmpx ) with a CCD camera (Orca ER,
Hamamatsu). Imaging time was limited to 15 minutes per coverslip, and all visibly labeled
cells per coverslip were photographed.
Images were processed with FIJI [92]. Regions of interest (ROIs) were manually drawn
around cells. Background subtraction was performed with the ImageJ “Rolling Ball” function
[102] with radius 5px (0.805µm, where mitochondrial radius is 0.25-0.6µm and minimum
mitochondrial length is typically 2-4µm [30]) and median filtered with radius 1px to remove
speckle noise. Images were then thresholded with the ImageJ “MaxEntropy” preset [51],
and individual particles were measured with the ImageJ “Analyze Particles” function to
determine area, aspect ratio, brightness, and form factor.
Form factor, Perimeter24πArea , is a measure of branching and shape complexity. A form factor
greater than 1 indicates a shape with high total curvature relative to area, which is typical of
highly branched shapes with complex perimeters. A form factor of 1 indicates a circle [78].
Aspect ratio, dmajoraxisdminoraxis is a measure of elongation. An aspect ratio greater than 1 indicates
an elongated ellipse or line, while an aspect ratio of 1 indicates a circle or square.
Particle measurements were analyzed with R [85]. Particle measurements were coerced
into a normal distribution using the Box-Cox power transformation, y(λ)i =



yλi − 1
λ if λ ?= 0,
ln(yi) if λ = 0
[18], with the parameter λ automatically chosen to maximize normality of the fitted model’s
residuals [109]. Transformed data was then analyzed with 2-way multiple linear regression.
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CHAPTER 3
RESULTS
Ciprofloxacin enhances effects of exogenous dopamine on cell viability
3.1 Differentiated SH-SY5Y cells are sensitized to dopaminergic
stress
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Figure 3.1: (a) Curve fits and (b) dopamine IC50(viability) values for differentiated (white)
and undifferentiated (red) cells. ∗ p < 0.05
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Figure 3.1a shows normalized fluorescence values and fitted sigmoidal functions for dif-
ferentiated and undifferentiated cells, while 3.1b shows IC50 values from the fitted curves.
Differentiated cells were found to have an IC50 value of 32.57µM (log(IC50) = −4.487 ±
0.1421), while undifferentiated cells were found to have an IC50 value of 88.59µM (log(IC50) =
−4.053 ± 0.06032). This difference was significant (p = 0.0429) as measured by an extra
sum of squares F test.
3.2 Ciprofloxacin, at physiologically relevant concentrations, is
not acutely toxic to SH-SY5Y cells
Cipro/mg/ml
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0
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****
Figure 3.2: Effects of ciprofloxacin, alone, on cell viability. ∗∗∗∗ p < 0.0001 compared to
untreated (black) cells.
Figure 3.2 suggests that, in an 18 hour period, physiologically relevant concentrations of
ciprofloxacin are not acutely toxic to differentiated SH-SY5Y cells. Viability of cells treated
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with 50-1250µg/ml ciprofloxacin was significantly lower than viability of untreated cells,
while viability of cells treated with ≤ 10µg/ml ciprofloxacin was not significantly lower than
that of untreated cells (ANOVA+Fisher’s LSD test, see A.2).
3.3 Dopamine reduces resazurin on its own
Figure 3.3 shows that, alone, neither dopamine nor ciprofloxacin exhibited any significant
background fluorescence. Ciprofloxacin did not reduce resazurin. However, dopamine did
reduce resazurin, as evidenced by significantly higher fluorescence in all resazurin-containing
wells with dopamine concentrations ≥ 50µM (ANOVA+Fisher’s LSD test, see A.1). The
increased fluorescence likely results from reduction of resazurin. Absorbance spectra in
Figure A.3 show a decrease in absorbance at 600nm coupled with an increase in absorbance
at 570nm, which is consistent with published spectra of resazurin and resorufin [83].
3.4 Ciprofloxacin enhances toxicity of dopamine
Figure 3.4 suggests that both 10µg/ml and 40µg/ml ciprofloxacin significantly enhance
dopamine toxicity. The dopamine IC50 value for 10µg/ml-treated cells was 18.06µM (log(IC50) =
−4.743±0.01317) compared to 25.57µM (log(IC50) = −4.592±0.01255) for untreated cells,
which was significant (F-test, p < 0.0001). The dopamine IC50 value for 40µg/ml-treated
cells was 10.09µM (log(IC50) = −4.972 ± 0.01213) compared to 23.69µM (log(IC50) =
−4.602 ± 0.01202) for untreated cells, which was significant (F-test, p < 0.0001). The
dopamine IC50 values of untreated cells in the 2 ciprofloxacin groups were not significantly
different (F-test, p = 0.5992).
Figure 3.5 suggests that ciprofloxacin dosages ≥ 10µg/ml significantly enhance dopamine
toxicity, while enhancement of dopamine toxicity in cells treated with 2µg/ml ciprofloxacin
approaches significance (F-test, see 3.1). Individual curve fits are shown in 3.6 and A.1.
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(d) Cipro and resazurin
Figure 3.3: Raw fluorescence values of drug-only controls for viability assay. See Table A.1
for significance, compared to media (black).
The dopamine IC50 value for 2µg/ml-treated cells was 19.06µM (log(IC50) = −4.720±
0.04486) compared to 23.69µM (log(IC50) = −4.625± 0.03012) for 0.64ng/ml treated cells,
which approached significance (F-test, p = 0.0873).
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Figure 3.4: (a) Curve fits and (b) dopamine IC50(viability) values for untreated (black) and
ciprofloxacin-treated (red) cells. ∗∗∗∗ p < 0.0001
[Cipro]/µg/ml log([Cipro]/µg/ml) log(IC50/µg/ml) IC50/µg/ml p
6.40e−004 −3.19 −4.625± 0.03012 2.369E−005 -
3.20e−003 −2.49 −4.622± 0.04261 2.385E−005 0.9545
1.60e−002 −1.80 −4.620± 0.04111 2.400E−005 0.9134
8.00e−002 −1.10 −4.613± 0.04013 2.436E−005 0.8090
4.00e−001 −0.397 −4.667± 0.03996 2.153E−005 0.4091
2.00e+000 0.301 −4.720± 0.04486 1.906E−005 0.0873
1.00e+001 1.00 −4.774± 0.04138 1.681E−005 0.0053
5.00e+001 1.70 −5.178± 0.03403 6.641E−006 < 0.0001
2.50e+002 2.40 −5.425± 0.03625 3.756E−006 < 0.0001
1.25e+003 3.10 −6.952± 0.1340 1.117E−007 < 0.0001
Table 3.1: p values for Figure 3.5
The dopamine IC50 value for 10µg/ml-treated cells was 16.81µM (log(IC50) = −4.774±
0.04138) compared to 23.69µM (log(IC50) = −4.625± 0.03012) for 0.64ng/ml treated cells,
which was significant (F-test, p = 0.0053).
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Figure 3.5: Dopamine IC50(viability) dependence on ciprofloxacin. See Table 3.1 for signif-
icance compared to untreated cells.
The dopamine IC50 value for 50µg/ml-treated cells was 6.641µM (log(IC50) = −5.178±
0.03403) compared to 23.69µM (log(IC50) = −4.625 ± 0.03012) for untreated cells, which
was significant (F-test, p < 0.0001).
The dopamine IC50 values for 250µg/ml and 1.25mg/ml-treated cells were 3.756µM
(log(IC50) = −5.425 ± 0.03625) and 111.7nM (log(IC50) = −6.952 ± 0.1340) compared
to 23.69µM (log(IC50) = −4.625± 0.03012) for untreated cells, which were both significant
(F-test, p < 0.0001).
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Figure 3.6: Curve fits for dopamine IC50(viability) dependence on ciprofloxacin. See Fig-
ure A.1 for curve fits plotted separately.
3.5 Effects of ciprofloxacin and dopamine on mitochondrial mor-
phology are inconclusive
Table 3.2 shows significant effects of dopamine and ciprofloxacin dosages, and a signifi-
cant interaction between dopamine and ciprofloxacin dose. As ciprofloxacin dose increases,
aspect ratio of mitochondria objects decreases. As dopamine dose increases, aspect ratio of
mitochondria objects decreases. As dopamine and ciprofloxacin dose increase together, the
decrease in aspect ratio is less than would be expected for either treatment alone. However,
the low R2 value suggests that very little variance in mitochondrial aspect ratio is actually
described by the model.
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Figure 3.10: Empirical distribution functions of aspect ratio
Table 3.3 shows significant effects of ciprofloxacin dosage. As ciprofloxacin dose increases,
form factor of mitochondria objects decreases, suggesting a ciprofloxacin-dependent loss of
mitochondrial reticulation. There are no significant effects of dopamine dose or interactions
between dopamine and ciprofloxacin dose. However, the very low R2 value suggests that
very little variance in mitochondrial form factor is actually described by the model.
Table 3.4 shows no significant effects of ciprofloxacin or dopamine dosage, suggesting that
neither treatment affects the area of mitochondrial objects.
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Figure 3.11: Aspect ratio histograms, grouped by treatment
Table 3.5 shows significant effects of dopamine and ciprofloxacin dosages, and a signifi-
cant interaction between dopamine and ciprofloxacin dose. As ciprofloxacin dose increases,
fluorescence intensity of mitochondrial objects increases. As dopamine dose increases, fluo-
rescence intensity of mitochondrial objects decreases. As dopamine and ciprofloxacin dose
increase together, the decrease in fluorescence intensity is greater than would be expected
for either treatment alone. However, the low R2 value suggests that very little variance in
mitochondrial aspect ratio is actually described by the model.
Because there were few of stained cells in some conditions (see Table A.3) and because
individual cells appeared to be very different by visual inspection, the analysis was repeated
(See Figure A.8) using a linear mixed-effects model [12] with per-cell random intercepts (90
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Estimate Std. Error t P r(> |t|) Significant?
(Intercept) 6.42e-01 1.51e-02 42.53 <2e-016 ***
Cipro -1.82e-03 4.67e-04 -3.89 0.00010 ***
Dopamine -2.29e-03 1.02e-03 -2.24 0.02522 *
Cipro:Dopamine 6.33e-05 2.72e-05 2.32 0.02002 *
Adjusted R2: 0.0113
Table 3.2: Aspect ratio linear model parameters
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(a) Empirical distribution functions of form factor vs. [cipro], grouped by [dopamine]
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(b) Empirical distribution functions of form factor vs. [dopamine], grouped
by [cipro]
Figure 3.12: Empirical distribution functions of form factor
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Figure 3.13: Form factor histograms, grouped by treatment
cells total). Significance was assessed by comparing the model to a random-effects-only null
model with the likelihood ratio test. P values for fit coefficients were also estimated using
the Satterthwaite approximation [62]. With mixed effects modeling, no model was better
than random effects alone, except for aspect ratio. For aspect ratio, drug treatments had
a significant effect (χ2(3) = 10.462, p = 0.01502); ciprofloxacin dosage had a significant
negative correlation with aspect ratio (p = 0.00143), suggesting that ciprofloxacin treatment
causes mitochondria to become less elongated. Effects of dopamine treatment and interaction
between ciprofloxacin and dopamine treatments were not significant. While mixed-effects
modeling is not typically used for morphological analysis of fluorescence images, the low
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Estimate Std. Error t P r(> |t|) Significant?
(Intercept) 3.96e-01 1.58e-002 25.09 ¡2.00E-016 ***
Cipro -1.34E-03 4.89e-004 -2.75 0.00602 **
Dopamine -9.70E-04 1.07e-003 -0.905 0.365
Cipro:Dopamine 3.72E-05 2.84e-005 1.31 0.191
Adjusted R2: 0.00539
Table 3.3: Form factor linear model parameters
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(b) Empirical distribution functions of area vs. [dopamine], grouped by
[cipro]
Figure 3.14: Empirical distribution functions of area
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Figure 3.15: Area histograms, grouped by treatment
R2 values of the fixed-intercept linear models suggest that most variance is due to per-cell
random effects and that significant effects are an artifact.
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Estimate Std. Error t P r(> |t|) Significant?
(Intercept) 2.785e-01 4.573e-02 6.090 1.46e-09 ***
Cipro -2.321e-03 1.415e-03 -1.641 0.101
Dopamine -1.103e-03 3.100e-03 -0.356 0.722
Cipro:Dopamine 4.879e-05 8.232e-05 0.593 0.554
Adjusted R2: 0.001987
Table 3.4: Area linear model parameters
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(b) Empirical distribution functions of intensity vs. [cipro], grouped by
[dopamine]
Figure 3.16: Empirical distribution functions of intensity
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Figure 3.17: Intensity histograms, grouped by treatment
Estimate Std. Error t P r(> |t|) Significant?
(Intercept) 13.9847503 0.1321777 105.803 <2.00e-16 ***
Cipro 0.0129202 0.0040888 3.160 0.00161 **
Dopamine -0.0330823 0.0089608 -3.692 0.000231 ***
Cipro:Dopamine -0.0005604 0.0002379 -2.355 0.0187 *
Adjusted R2: 0.06329
Table 3.5: Intensity linear model parameters
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CHAPTER 4
DISCUSSION
4.1 Dopamine sensitivity dependence on cell differentiation
Dopamine sensitivity of SH-SY5Y cells depends on differentiation status, and the dopamine
IC50 value agrees with one measured in differentiated SH-SY5Y cells using a similar as-
say [45]. This suggests that, if differentiated cells express DAT and undifferentiated cells do
not, then the target of dopamine toxicity could be intracellular.
30µM is considerably higher than the binding Km of dopamine at the human dopamine
transporter, measured to be 2µM in intact cells [71]. This suggests that (uptake of dopamine
by DAT is not the rate limiting step in cell viability inhibition), or that the effective con-
centration of dopamine is lower than the applied dosage. As dopamine toxicity is likely
not mediated by a specific binder of dopamine, the former explanation is plausible. How-
ever, dopamine is known to undergo auto-oxidation and dopamine concentrations greater
than 100µM were visibly black after overnight incubation, so the effective concentration of
dopamine is likely lower than expected. Intermediate products of dopamine autooxidation,
such as dopamine quinone and dopamine semiquinone, are also thought to mediate toxicity.
Another possible confound is cell proliferation. While undifferentiated SH-SY5Y cells
proliferate, differentiated SH-SY5Y cells do not [50]. So, the density of undifferentiated cells
is likely higher than the density of differentiated cells during drug treatment and viability
assay, leading to faster reduction of resazurin in wells seeded with undifferentiated cells.
Differentiation status should be confirmed by immunofluorescence staining of DAT and
other differentiation markers. To control for cell proliferation, resazurin fluorescence may
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be measured in individual cells, rather than in bulk media by, by using fluorescence assisted
cell sorting (FACS). FACS is also sensitive to heterogeneity within cell populations, and
would facilitate measuring correlation of DAT expression to cell viability. To determine
the mechanism of dopamine toxicity, dopamine-treated cells may be rescued by targeting
relevant mechanisms– For example, by applying antioxidants such as reduced glutathione,
N-acetylcysteine, or tocopherols, DAT inhibitors such as GBR 12935, or VMAT inhibitors
such as reserpine. The antioxidant ascorbate was found to increase dopamine IC50 (see
Figure A.2), but this effect is likely an artifact of direct resazurin reduction by ascorbate.
4.2 Viability dependence on ciprofloxacin
In an 18 hour period, physiologically relevant concentrations of ciprofloxacin are not
acutely toxic to differentiated SH-SY5Y cells. The estimate of physiologically relevant con-
centration for the current study is taken from the recommended cell culture ciprofloxacin
dose of 10µg/ml, which is used for long-term maintenance of in vitro cell cultures [2]. In hu-
mans treated with clinical doses of ciprofloxacin, concentrations have been measured at ≈1-
5µg/g [27,67] in excised brain tissue, and at ≈0.5-2.5µg/ml in cerebrospinal fluid (CSF) [33],
with brain tissue concentration 2-20 times that of CSF [27] and CSF concentration 0.5-0.8
times that of blood plasma [33, 67]. Kinetic modeling of tissue uptake suggests that brain
tissue concentrations may peak at ≈10µg/g, with [27].
In vitro studies of ciprofloxacin cytotoxicity suggest that the effect is maximized after
several days, although significant increases of ROS and stress biomarkers are seen after 12-24
hours of treatment at 10µg/ml [42,48,65]. In vivo studies show a large, significant, increase
of oxidative stress biomarkers over several months of ciprofloxacin treatment [48], and clinical
ciprofloxacin treatment typically lasts several weeks.
Taken together, this establishes 10µg/ml as a subthreshold ciprofloxacin dose for 24-hour
experiments and demonstrates that higher ciprofloxacin doses are significantly cytotoxic over
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a 24-hour period. Further studies may benefit from using lower ciprofloxacin dosages and
longer treatment times.
4.3 Viability assay interference by dopamine
At 250µM , the highest concentration used in dose-response experiments, dopamine sig-
nificantly reduced resazurin by an amount corresponding to a fluorescence increase of 164AU
(≈ 8.2% normalized fluorescence); With 50µM dopamine, resorufin fluorescence is increased
by 61AU (≈ 3% normalized fluorescence). This should be expected, given that dopamine
and its metabolites all have reduction potentials sufficiently low to reduce resazurin (see
Table 1.1), including polydopamine via surface-exposed catechol/quinone groups [72]. This
suggests that the effects of high dopamine doses on cell viability are underestimated.
The simplest way to minimize redox artefacts in the resazurin viability assay is to remove
treatment media prior to running the viability assay. Media was not changed (in all viability
experiments except for Experiment 2.2) under the rationale that cells are increasingly likely
to die or detach from plates the more they are kept outside of the incubator and subjected to
the mechanical stress of media changes– Especially when their viability is already impaired
due to the drug treatments (see Experiment 2.7). Indeed, the intra-group fluorescence vari-
ation in Experiment 2.2 is much higher than in subsequent viability experiments, where
resazurin was added directly to the treatment media This suggests that handling stress dras-
tically affects the viability assay, or that drug treatment effects on fluorescence are an artifact
and intragroup variability results from compounded pipetting error. The latter possibility is
unlikely given that direct resazurin reduction by dopamine or its oxidation products causes
effects of dopamine on cell viability to be under-reported, while ciprofloxacin does not inter-
fere with the assay. Some redox-active dopamine metabolites (DOPAC, DOPAL) are only
accessible through enzymatic reactions and so were not included in the cell-free control.
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While reduction of resazurin to fluorescent resorufin is considered irreversible, resorufin
can be converted back to resazurin by H2O2 (generated during intracellular oxidation of
dopamine), although this process typically requires catalysis by peroxidase. Resorufin is also
further reversibly reduced to non-fluorescent dihydroresorufin (E ?o = −51mV ) [53, 81]. As
this reduction potential is lower than the reduction potential of resazurin (E ?o = +380mV ) [1],
resorufin is not reduced by as many chemical species as resazurin and in practice the con-
version of resorufin into dihydroresorufin occurs slowly in most cells [107]. Nevertheless, re-
sorufin is known to be reduced into dihydroresorufin by the ER enzyme NADPH-cytochrome
P450 reductase (Eh = +159mV ) and is kinetically favored in tissues with high expres-
sion of NADPH-cytochrome P450 reductase, such as liver [28]. As the reduction poten-
tials of most dopamine oxidation products are sufficiently low to reduce resorufin, however
(Eh ≈ +100−+250mV ), it is possible that resorufin reduction caused viability of dopamine-
treated cells to be underestimated and caused the effect of dopamine on cell viability to be
overestimated. Or, higher NADPH-cytochrome P450 activity in healthy cells could cause
the effect of dopamine on cell viability to be underestimated.
Resorufin, with a pKa of 7.25, exhibits strong fluorescence quenching upon protona-
tion [35, 107]. While media pH was colorimetrically monitored with phenol red and did not
appear to depend on treatment condition, phenol red has a pKa of 8.00 and so resorufin is
expected to be more sensitive to media pH changes close to 7.3-7.4. Differences in media pH
between wells would cause cell viability to be under- or over-estimated, for lower and higher
pH respectively. If cells with impaired respiratory capacity increase anaerobic glycolysis
and lactate production, then the effect of dopamine on cell viability could be overestimated.
However, other contributions to media pH such as cell death make the size of this effect
difficult to estimate. In resazurin reduction assays, pH could be controlled for by spiking
plates with a small amount of resorufin at the beginning of the viability assay and imme-
diately measuring fluorescence to determine pH, provided this did not compress the assay’s
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dynamic range. Buffering agents stronger than bicarbonate should be chosen carefully, as
most buffers suitable for cell culture can participate in redox reactions [37].
In order to minimize redox and pH artefacts, the viability assay should not be per-
formed in drug treatment media, or it should be redox-inactive and pH-insensitive. The
former condition can be most easily accomplished by reading out resorufin fluorescence by
FACS in phosphate buffer, so that dopamine is washed out but detached adherent cells are
not excluded from the assay. A FACS readout could also multiplex additional colorimet-
ric live/dead stains such as ethidium, and intrinsic viability indicators such as forward and
side light scattering [98]. The latter condition, suitable for well plates and high throughout
screening, can be accomplished by using non-redox based viability or stress assays. These
include ELISAs directed against oxidative stress biomarkers such as carbonylated proteins,
the lipids 4-HNE and MDA, and the oxidized nucleotide 8-OHdG [48, 91].
Adding a cell-impermeable reducing reagent such as TCEP during drug treatment may
prevent extracellular autooxidation of dopamine, which may lead to a more consistent de-
livery of dopamine, rather than its oxidation products, over the treatment period.
In summary, cell-free controls suggest that dopamine directly reduces resazurin leading
to overestimated cell viability at high dopamine doses. With 250µM dopamine, resorufin
fluorescence is increased by 164AU (≈ 8.2% normalized fluorescence); With 50µM dopamine,
resorufin fluorescence is increased by 61AU (≈ 3% normalized fluorescence). Other redox and
pH effects not controlled for may also alter estimates of viability dependence on dopamine.
However, ciprofloxacin did not appear to interfere with the resazurin reduction assay. As
dopamine treatments are identical between each ciprofloxacin treatment group, observed
dependence of dopamine IC50 on ciprofloxacin are likely to be meaningful.
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4.4 Combined dopamine and ciprofloxacin treatment
The data shown in Figures 3.4 and 3.5 support the hypothesis that ciprofloxacin enhances
dopamine toxicity, as cells treated with ≥10µg/ml had significantly lower dopamine IC50
values for viability, showing that ciprofloxacin-treated cells suffered a 50% loss of viability at
lower dopamine dosages than untreated cells. Also, there was a dose-dependent relationship
between ciprofloxacin and dopamine IC50(viability) decrease. This is perhaps not surprising
given that ciprofloxacin dosages ≥50µg/ml caused a dose-dependent cell viability decrease in
the absence of dopamine, but is nevertheless consistent with the hypothesis. Ciprofloxacin
dosages lower than 10µg/ml warrant further investigation, perhaps with treatment times
longer than 24 hours.
In contrast to the dopamine IC50(viability) values for differentiated SH-SY5Y cells re-
ported here, previous studies have reported extracellular dopamine IC50(viability) values in
SH-SY5Y cells to be 100-200µM [14,36,40,45,113]. However, these studies all used undiffer-
entiated SH-SY5Y cells. Also, in these studies all cell culture and dopamine treatment took
place in media containing 10% serum, while we used 1% serum. Extracellular dopamine tox-
icity in cultured cells has been reported to have a strong dependence on serum content, with
serum deprivation causing a twofold increase in dopamine-induced cell death [55]. Taking
into account the difference in serum content, the dopamine IC50(viability) value of 88µM
found for undifferentiated cells is consistent with previous reports.
Dopamine IC50(viability) values of 23µM to 32µM for untreated differentiated SH-SY5Y
cells are consistent with reported LD50 values for dopamine in cultured rat striatal neurons
of 25µM [76]. They are also consistent with reported IC50 values of 8-20µM for activity
inhibition of various mitochondrial enzymes by dopamine in mitochondria isolated from
SH-SY5Y cells [14]. The range in dopamine IC50(viability) values between experiments
conducted on different days and on different passages of SH-SY5Y cells suggests a strong
dependence of dopamine sensitivity on cell line phenotype and differentiation status.
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While potentiation of dopamine toxicity by ciprofloxacin has not been examined else-
where, it is consistent with other reports of cooperative toxicity between mitochondrial
inhibitors and dopaminergic drugs. For example, subthreshold doses of the mitochondrial
inhibitor MPTP and the dopaminergic stressor methylphenidate, in combination, have been
show to cause significant death of substantia nigra dopaminergic neurons in mice [88]. And,
subthreshold doses of the mitochondrial inhibitor malonate and exogenous dopamine, in
combination, have been shown to cause significant death of cultured striatal dopaminer-
gic neurons in mice [76]. The difference between these studies and the current one is that
ciprofloxacin is not a direct mitochondrial inhibitor, but instead acts as an indirect mitochon-
drial inhibitor by interfering with mitochondrial DNA maintenance and protein turnover.
4.5 Mitochondrial morphology
Regression analysis of aspect ratio suggests that both ciprofloxacin and dopamine cause
mitochondria to become less elongated, which is consistent with mitochondrial fragmen-
tation. This is expected, as decrease in aspect ratio is reported for various treatments
which induce mitochondrial stress [47, 114, 115]. However, the positive regression coefficient
of [Ciprofloxacin]*[Dopamine] is unexpected, because it suggests that combined treatment
with both drugs protects against fragmentation.
Regression analysis of form factor suggests that ciprofloxacin causes mitochondria to
become less reticulated, which is consistent with mitochondrial fragmentation. This is ex-
pected, as decrease in form factor is reported for various treatments which induce mito-
chondrial stress [47, 114, 115]. However, the lack of dependence on dopamine is unexpected,
as dopamine is known to induce mitochondrial stress and is therefore expected to cause a
decrease in form factor.
Regression analysis of intensity suggests that ciprofloxacin treatment causes mitochon-
drial fluorescence intensity to become brighter, while dopamine treatment causes mitochon-
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drial fluorescence intensity to become dimmer and combined treatment causes fluorescence
intensity to become dimmer than would be expected for either treatment alone. If fluores-
cence intensity is a measure of membrane potential, this suggests that ciprofloxacin treatment
hyperpolarizes mitochondria, dopamine treatment depolarizes mitochondria, and combined
treatment depolarizes mitochondria more than would be expected for either treatment alone.
The effect of ciprofloxacin is unexpected, because it is reported to cause a dose-dependent
decrease in mitochondrial membrane potential [5, 42]. The effect of dopamine is expected
because dopamine is reported to cause dose-dependent decrease in mitochondrial membrane
potential [15]. The interaction between ciprofloxacin and dopamine support the hypothesis,
because it suggests that combined treatment with ciprofloxacin and dopamine is especially ef-
fective at depolarizing mitochondria, which is a biomarker of mitochondrial dysfunction [70].
Regression analysis of area suggests that neither ciprofloxacin nor dopamine treatments
affect area of individual mitochondria. This is unexpected because fragmentation of a mito-
chondrial network into smaller objects is expected to decrease object size; however, effects
of mitochondrial stress on area have not been previously reported.
The low R2 values of the linear models suggest that they have little predictive power and
are likely not physically meaningful. To estimate the effects of ciprofloxacin and dopamine
treatments on mitochondrial morphology, more cells should be imaged under less stressful
imaging conditions. Preparation for imaging selects for healthy cells, as washing can remove
cells which are not tightly adherent. Given that mitochondrial morphology is related to
cell health and all treatments are expected to disrupt cell health, it is likely that treatment
effects on mitochondrial morphology are under-reported.
Morphology measurements made using the MitoTracker dye are presumably sensitive to
mitochondrial membrane potential and respiratory capacity. The dye is applied as a neutral
profluorophore, which is oxidized to a cationic fluorophore inside mitochondria. The cationic
fluorophore is retained inside mitochondria due to the organelles’ negative potential relative
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to cytoplasm [101]. While MitoTracker Green is reported to stain mitochondria irrespective
of membrane potential, it is completely plausible that mitochondria with decreased respi-
ratory ability may show decreased MitoTracker fluorescence, and depolarized mitochondria
may not retain the fluorophore. Therefore, MitoTracker may selectively stain healthy cells.
Transfecting cells with a mitochondrion-targeted fluorescent protein may avoid this problem.
Because epifluorescence microscopy can only resolve a single focal plane with out-of-focus
objects appearing as a blur, dense mitochondria near the nucleus were not included in par-
ticle analysis. Images of mitochondrial morphology could be improved by using confocal
microscopy instead of epifluorescence microscopy, allowing all mitochondria to be imaged as
well as increasing resolution and signal to noise ratio.
4.6 Future directions
From a clinical standpoint, the effect of ciprofloxacin on oxidative stress should be in-
vestigated in vivo, using a rodent model of dopaminergic stress (L-DOPA, amphetamine,
reserpine) or oxidative stress (chronic rotenone). Loss of TH-positive cell bodies should be
examined in the SN and VTA, as well as in olfactory bulb interneurons, retinal interneurons,
and adrenal chromaffin cells. If the in vitro results presented here are recapitulated in an in
vivo model, this strongly suggests that the use of ciprofloxacin and related quinolone antibi-
otics be minimized in patients who are treated with dopaminergic stimulants or L-DOPA,
who use dopaminergic drugs of abuse, or who are otherwise at risk for oxidative stress from
environmental toxins.
The hypothesis that cytotoxicity of combined ciprofloxacin and dopamine is mediated by
mitochondrial ROS remains untested. From a practical clinical perspective the mechanism
is somewhat irrelevant; the most important outcome is simply whether or not damage oc-
curs, and the simplest intervention is to avoid treatment with fluoroquinolones (or similar
antibiotics [48]) or to avoid the pharmacological dopaminergic stressor. In some cases this
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intervention may not be possible, such as cases where patients are undergoing levodopa ther-
apy for Parkinson’s disease or have familial loss-of-function in superoxide dismutase. In the
interest of developing interventions against antibiotic-enhanced dopaminergic stress, such
as mitochondria-targeted antioxidants, ELISAs directed against oxidative stress biomarkers
should be used to confirm the mechanism of action and to screen for pharmacological rescues.
From a drug screening standpoint, redox interactions between the viability assay and
the dopaminergic challenge make the system unsuitable for screening for compounds that
rescue ciprofloxacin-induced sensitivity to dopamine. This is a recognized problem in drug
screening; catechols and quinones are both examples of “pan-assay interfering” compounds
(PAINS) known to interfere with in vitro activity screening [8]. However, the simple and
cheap dopamine-resazurin system may provide a useful preliminary toxicology test for screen-
ing known redox-inactive compounds (such as ciprofloxacin), provided that the effect of assay
interference does not overwhelm the effect of treatments being screened. An ELISA or FACS
based assay [48, 91] could provide a more useful toxicology screen for general use.
While I suggest that the mechanism underlying ciprofloxacin- and dopamine-induced
loss of viability is due to mitochondrial ROS production, this is only tested indirectly by
resazurin reduction and mitochondrial morphology. Reactive oxygen species (O−2 , O•2) and
ROS-derived species (HO•, H2O2, ONOO•) may be profiled using commercially available
dye-based kits. Engineered fluorescent proteins have been reported as sensors of ROS, but
are currently believed to sense mitochondrial pH instead of ROS [94, 110]. Downstream
biomarkers of pathological ROS generation such as lipid peroxidation and caspase activa-
tion may be assayed using commercially available dye-based kits and immunofluorescence
methods.
Because unhealthy adherent cells tend to detach from their substrates, fluorescence-based
experiments should be repeated using flow cytometry to include the population of cells which
may have detached during solution changes.
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In order to demonstrate clinical relevance, these experiments should be repeated in vivo
using a variety of fluoroquinolone antibiotics in addition to ciprofloxacin, and with clinically
relevant dopaminergic stressors such as L-DOPA, amphetamine, reserpine, and rotenone in
place of exogenous dopamine. Using a rat model, cell viability can be assessed by immunoflu-
orescent staining of tyrosine hydroxylase positive cells in olfactory bulb and substantia nigra
tissue slices. Animals used in these experiments should also be subjected to olfactory dis-
crimination tests and gait assays in order to determine whether loss of TH+ cells induced
by drug treatments leads to sensory or motor deficits.
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APPENDIX
ADDITIONAL FIGURES
Uncorrected Fisher’s LSD Mean Diff./AU Significant? Summary Individual P Value
0 vs. 6250 -1017 Yes **** <0.0001
0 vs. 1250 -587.9 Yes **** <0.0001
0 vs. 250 -164.0 Yes **** <0.0001
0 vs. 50 -61.14 Yes * 0.0119
0 vs. 10 -5.378 No ns 0.8214
0 vs. 2 27.12 No ns 0.2568
0 vs. 0.4 38.17 No ns 0.1119
0 vs. 0.08 14.40 No ns 0.5459
0 vs. 0.016 -5.853 No ns 0.8059
0 vs. 0.0032 3.903 No ns 0.8698
Table A.1: p values for Figure 3.3
Uncorrected Fisher’s LSD Mean Diff./% Significant? Summary Individual p Value
0 vs. 1250 34.94 Yes **** <0.0001
0 vs. 250 18.44 Yes **** <0.0001
0 vs. 50 7.026 Yes **** <0.0001
0 vs. 10 -1.488 No ns 0.3363
0 vs. 2 -0.1432 No ns 0.9262
0 vs. 0.4 -1.718 No ns 0.2670
0 vs. 0.08 -0.1813 No ns 0.9066
0 vs. 0.016 -0.5984 No ns 0.6986
0 vs. 0.0032 -0.1341 No ns 0.9308
0 vs. 0.00064 0.08871 No ns 0.9542
Table A.2: p values for Figure 3.2
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Cipro
0 2 10 50
0 9 8 11 3
Dopamine 10 10 7 9 2
50 9 13 6 3
Table A.3: Number of cells analyzed per condition in Experiment 2
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Figure A.1: Curve fits for dopamine IC50(viability) dependence on ciprofloxacin, also shown
in Figure 3.6
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Figure A.2: (a) Curve fits and (b) dopamine IC50(viability) values for untreated (black) and
ascorbate-treated (red) cells. ∗∗∗∗ p < 0.0001
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Figure A.3: Normalized absorbance spectra of resazurin, without (blue) and with (orange)
250µM dopamine. Oxidized dopamine absorbance reaches half-maximal absorbance at 470
and overlaps with absorbance of media at concentrations below 250µM (data not shown).
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Figure A.4: Transformed aspect ratio linear model residuals
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Figure A.5: Transformed form factor linear model residuals
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Figure A.6: Transformed area linear model residuals
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Figure A.7: Intensity linear model residuals
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> ###############################################################
> ## Form Factor
> modelFF <- lmer(FormFactor ~ Cipro*Dopamine+ (1|uniqueId), data=dataset,REML=FALSE)
> modelFFnull <- lmer(FormFactor ~ (1|uniqueId), data=dataset,REML=FALSE)
> anova(modelFFnull,modelFF)
Data: dataset
Models:
object: FormFactor ~ (1 | uniqueId)
..1: FormFactor ~ Cipro * Dopamine + (1 | uniqueId)
Df AIC BIC logLik deviance Chisq Chi Df Pr(>Chisq)
object 3 7666.9 7682.6 -3830.4 7660.9
..1 6 7668.4 7699.9 -3828.2 7656.4 4.4257 3 0.219
> summary(modelFF)
Linear mixed model fit by maximum likelihood
t-tests use Satterthwaite approximations to degrees of freedom [’merModLmerTest’]
Formula: FormFactor ~ Cipro * Dopamine + (1 | uniqueId)
Data: dataset
AIC BIC logLik deviance df.resid
7668.4 7699.9 -3828.2 7656.4 1400
Scaled residuals:
Min 1Q Median 3Q Max
-0.7402 -0.4003 -0.2961 0.0288 20.9352
Random effects:
Groups Name Variance Std.Dev.
uniqueId (Intercept) 0.1813 0.4258
Residual 13.4047 3.6612
Number of obs: 1406, groups: uniqueId, 90
Fixed effects:
Estimate Std. Error df t value Pr(>|t|)
(Intercept) 2.9338001 0.1911892 50.8400000 15.345 <2e-16 ***
Cipro -0.0116996 0.0058869 54.3400000 -1.987 0.0519 .
Dopamine -0.0063262 0.0130162 47.0700000 -0.486 0.6292
Cipro:Dopamine 0.0001648 0.0003519 37.4400000 0.468 0.6423
---
Signif. codes: 0 *** 0.001 ** 0.01 * 0.05 . 0.1 1
Correlation of Fixed Effects:
(Intr) Cipro Dopamn
Cipro -0.736
Dopamine -0.553 0.386
Cipro:Dopmn 0.441 -0.516 -0.787
> ###############################################################
> ## Aspect ratio
> modelAR <- lmer(AR ~ Cipro*Dopamine+ (1|uniqueId), data=dataset,REML=FALSE)
> modelARnull <- lmer(AR ~ (1|uniqueId), data=dataset,REML=FALSE)
> anova(modelARnull,modelAR)
Data: dataset
Models:
object: AR ~ (1 | uniqueId)
..1: AR ~ Cipro * Dopamine + (1 | uniqueId)
Df AIC BIC logLik deviance Chisq Chi Df Pr(>Chisq)
object 3 7030.2 7046.0 -3512.1 7024.2
..1 6 7025.8 7057.2 -3506.9 7013.8 10.462 3 0.01502 *
---
Signif. codes: 0 *** 0.001 ** 0.01 * 0.05 . 0.1 1
> summary(modelAR)
Linear mixed model fit by maximum likelihood
t-tests use Satterthwaite approximations to degrees of freedom [’merModLmerTest’]
Formula: AR ~ Cipro * Dopamine + (1 | uniqueId)
Data: dataset
AIC BIC logLik deviance df.resid
7025.8 7057.2 -3506.9 7013.8 1400
Scaled residuals:
Min 1Q Median 3Q Max
-1.0267 -0.5551 -0.3352 0.1172 10.6276
Random effects:
Groups Name Variance Std.Dev.
uniqueId (Intercept) 0.1921 0.4383
Residual 8.4280 2.9031
Number of obs: 1406, groups: uniqueId, 90
Fixed effects:
Estimate Std. Error df t value Pr(>|t|)
(Intercept) 3.5760023 0.1614607 74.1000000 22.148 < 2e-16 ***
Cipro -0.0164079 0.0049626 77.9600000 -3.306 0.00143 **
Dopamine -0.0146119 0.0110189 68.7200000 -1.326 0.18921
Cipro:Dopamine 0.0004862 0.0003000 57.3800000 1.621 0.11059
---
Signif. codes: 0 *** 0.001 ** 0.01 * 0.05 . 0.1 1
Correlation of Fixed Effects:
(Intr) Cipro Dopamn
Cipro -0.736
Dopamine -0.556 0.389
Cipro:Dopmn 0.439 -0.516 -0.782
> ###############################################################
> ## Area
> modelArea <- lmer(Area ~ Cipro*Dopamine+ (1|uniqueId), data=dataset,REML=FALSE)
> modelAreanull <- lmer(Area ~ (1|uniqueId), data=dataset,REML=FALSE)
> anova(modelAreanull,modelArea)
Data: dataset
Models:
object: Area ~ (1 | uniqueId)
..1: Area ~ Cipro * Dopamine + (1 | uniqueId)
Df AIC BIC logLik deviance Chisq Chi Df Pr(>Chisq)
object 3 9578 9593.8 -4786.0 9572
..1 6 9579 9610.5 -4783.5 9567 4.9612 3 0.1747
> summary(modelArea)
Linear mixed model fit by maximum likelihood
t-tests use Satterthwaite approximations to degrees of freedom [’merModLmerTest’]
Formula: Area ~ Cipro * Dopamine + (1 | uniqueId)
Data: dataset
AIC BIC logLik deviance df.resid
9579.0 9610.5 -4783.5 9567.0 1400
Scaled residuals:
Min 1Q Median 3Q Max
-1.0355 -0.3663 -0.2650 -0.0101 11.6550
Random effects:
Groups Name Variance Std.Dev.
uniqueId (Intercept) 2.356 1.535
Residual 51.063 7.146
Number of obs: 1406, groups: uniqueId, 90
Fixed effects:
Estimate Std. Error df t value Pr(>|t|)
(Intercept) 4.332190 0.451275 60.980000 9.600 8.33e-14 ***
Cipro -0.024186 0.013836 62.840000 -1.748 0.0853 .
Dopamine -0.001041 0.030943 56.780000 -0.034 0.9733
Cipro:Dopamine -0.000211 0.000851 50.130000 -0.248 0.8052
---
Signif. codes: 0 *** 0.001 ** 0.01 * 0.05 . 0.1 1
Correlation of Fixed Effects:
(Intr) Cipro Dopamn
Cipro -0.737
Dopamine -0.561 0.393
Cipro:Dopmn 0.438 -0.516 -0.774
> ###############################################################
> ## Greyscale intensity
> modelMean <- lmer(Mean ~ Cipro*Dopamine+ (1|uniqueId), data=dataset,REML=FALSE)
> modelMeannull <- lmer(Mean ~ (1|uniqueId), data=dataset,REML=FALSE)
> anova(modelMeannull,modelMean)
Data: dataset
Models:
object: Mean ~ (1 | uniqueId)
..1: Mean ~ Cipro * Dopamine + (1 | uniqueId)
Df AIC BIC logLik deviance Chisq Chi Df Pr(>Chisq)
object 3 16822 16838 -8407.9 16816
..1 6 16826 16857 -8406.9 16814 2.0079 3 0.5708
> summary(modelMean)
Linear mixed model fit by maximum likelihood
t-tests use Satterthwaite approximations to degrees of freedom [’merModLmerTest’]
Formula: Mean ~ Cipro * Dopamine + (1 | uniqueId)
Data: dataset
AIC BIC logLik deviance df.resid
16825.8 16857.3 -8406.9 16813.8 1400
Scaled residuals:
Min 1Q Median 3Q Max
-2.8360 -0.5931 -0.1014 0.4707 6.3029
Random effects:
Groups Name Variance Std.Dev.
uniqueId (Intercept) 14546 120.61
Residual 7382 85.92
Number of obs: 1406, groups: uniqueId, 90
Fixed effects:
Estimate Std. Error df t value Pr(>|t|)
(Intercept) 281.71826 22.90960 89.51000 12.297 <2e-16 ***
Cipro 0.37140 0.70361 89.02000 0.528 0.599
Dopamine -1.13475 1.61716 88.23000 -0.702 0.485
Cipro:Dopamine -0.01002 0.04582 87.53000 -0.219 0.827
---
Signif. codes: 0 *** 0.001 ** 0.01 * 0.05 . 0.1 1
Correlation of Fixed Effects:
(Intr) Cipro Dopamn
Cipro -0.734
Dopamine -0.582 0.405
Cipro:Dopmn 0.436 -0.519 -0.750
Figure A.8: Linear mixed effect model
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